Results 41 to 50 of about 74,231 (262)

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Folwaczny, Christian, Glas, J., Konig, A., Martin, K., Schaefer, M., Schiemann, Uwe, Schmidt, F., Simperl, C., Torok, P.   +8 more
core   +1 more source

Introduction to the database “efficacy of different treatment modalities for lower respiratory tract infections in children”

Pediatric Discovery, EarlyView.
This article introduces a national, multicenter, prospective, non‐interventional, observational registry study, which established a comprehensive and sustainable database of lower respiratory tract infection in children. This database will help improve the scientific research efficiency of clinicians and facilitate the exploration of underlying ...
Yu Deng, Bing Hu, Yingxue Zou, Zhengxiu Luo, Guangli Zhang, Jinhai Ma, Changshan Liu, Xiaoyan Dong, Huifen Zi, Chuangli Hao, Rongjun Lin, Xiangrong Zheng, Bingfei Li, Fenhua Chen, Mei Fang, Weimin Tian, Zhiqiang Zhuo, Deyu Zhao, Zhimin Chen, Yuejie Zheng, Jingyang Zheng, Yong Yin, Qiuyu Tang, Liqun Wu, Li Gu, Jinzhun Wu, Liyi He, Tao Ai, Ning Wang, Minjun Zhang, Hailin Zhang, Hanmin Liu, Youxiang Zhang, Jianguo Hong, Zhiying Han, Yunbo Mo, Hongmei Qiao, Zhiliang Tian, Zengni Li, Quan Lu, Enmei Liu   +40 more
wiley   +1 more source

Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program [PDF]

, 2016
Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir ...
Andreoni, M., Angarano, G., Antinori, A., Boffa, N., Bruno, R., Cacopardo, B., Castelli, F., Cattelan, A., Chirianni, A., De Luca, A., Di Biagio, A., Di Perri, G., D’Arminio Monforte, A., Galli, M., Gentilotti, E., Giacometti, A., Gori, A., Lazzarin, A., Maggiolo, F., Mastroianni, C. M., Mussini, C., Parruti, G., Pasquazzi, C., Pennica, A., Puoti, M., Ricciardi, A., Rizzardini, G., Sarmati, L., Sighinolgi, L., Taliani, G., Teti, E., Vullo, V.   +31 more
core   +1 more source

Pterostilbene Exhibits Broad‐Spectrum Antiviral Activity by Targeting the Enterovirus Capsid, Inactivating Viral Particles, Blocking Viral Binding, and Protecting Mice From Lethal EV‐A71 Challenge

Phytotherapy Research, Volume 39, Issue 6, Page 2672-2688, June 2025.
Pterostilbene (Pte) binds to the VP1 hydrophobic pocket of enteroviruses, stabilizing the viral capsid and preventing uncoating and RNA release. In vitro, Pte inactivates virions and impairs viral attachment, entry, and replication. In vivo, oral administration of Pte in hSCARB2‐transgenic mice reduces clinical symptoms and improves survival ...
Kuan‐Ting Chuang, Siao‐Cian Pan, Bor‐Luen Chiang, Shih‐Hsun Chen, Min‐Hsiung Pan, Yu‐Li Chen, Cheng‐Sheng Lin, Chun‐Kai Pan, Jing‐Yi Lin, Yu‐Li Lin   +9 more
wiley   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]

, 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH, Castera, L, Church, DR, Dee, L, Graham, C, Jacobson, IM, Litwin, AH, Mehta, SH, Muir, A, New Paradigm of HCV Therapy Meeting Participants, Poynard, T, Razavi, H, Schooley, RT, Sulkowski, MS, Talal, AH, Thomas, DL, Ward, JW, Zeuzem, S   +17 more
core   +2 more sources

Ribavirin and its analogs: Сan you teach an old dog new tricks?

Тонкие химические технологии, 2019
The review article focuses on the current state of synthetic and biological studies of ribavirin analogs. Ribavirin is a broad-spectrum nucleoside antiviral drug with a 50-year long history of research and application, but its mechanism of action still ...
M. V. Chudinov
doaj   +1 more source

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

PLoS Neglected Tropical Diseases, 2022
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable.
Alex P Salam, Alexandre Duvignaud, Marie Jaspard, Denis Malvy, Miles Carroll, Joel Tarning, Piero L Olliaro, Peter W Horby   +7 more
doaj   +1 more source

Exploring the impact of a chemical disinfectant and an antiviral drug for RNA virus management in the Mediterranean fruit fly mass‐rearing

Insect Science, EarlyView.
Abstract The Mediterranean fruit fly is an agricultural pest of a wide variety of fruit crops. An effective method to counteract them in the field is through the application of the sterile insect technique, which requires the mass‐production of sterile males.
Luis Hernández‐Pelegrín, Pablo García‐Castillo, Marta Catalá‐Oltra, Óscar Dembilio, Vera I.D. Ros, Salvador Herrero   +5 more
wiley   +1 more source

SOFOSBUVIR AND RIBAVIRIN

The Professional Medical Journal, 2018
Objectives: This study was conducted to evaluate the 16-weeks versus 24-weeks efficacy of sofosbuvir and ribavirin in HCV genotype-3a infection. Study Design: Open labeled, single center, longitudinal study. Setting: Khyber Medical College and Khyber Teaching Hospital, Peshawar.
Abid Shah, Nizamud din, Jamalud Din, Waheed Iqbal   +3 more
openaire   +2 more sources

Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

Andrology, EarlyView.
Abstract Background Growing evidence indicates that paternal condition significantly influences pregnancy outcomes and offspring health. However, assessing the safety of paternal drug exposure via randomized controlled trials poses ethical challenges, and relevant clinical studies consume a lot of resources to evaluate only a few drugs.
Yanbin Zeng, Wanlong Lin, Wei Zhuang
wiley   +1 more source